23-Valent Pneumococcal Polysaccharide Vaccine Market Report

Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, Status and Forecast 2014-2026

  • POSTDATE：Oct 14, 2019
  • PAGES：214
  • REPORT CODE：GMM319298
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The 23-Valent Pneumococcal Polysaccharide Vaccine market was valued at 1536 Million US$ in 2018 and is projected to reach 3203 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 9.62% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Segmentations:

    By Player:

    • Sanofi S.A.

    • Merck & Co.

    • GlaxoSmithKline Plc.

    • Pfizer Inc

    • Serum Institute of India.

    • Eli Lilly and Company.

    • AstraZeneca

    • Sanofi SA

    • Biogen Inc

    • Baxter International Inc

    By Type:

    • Single Dose Vial

    • Pre-filled Syringe

    By End-User:

    • For Children (2-10)

    • For Person (10-64)

    • For The old (≥65)

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of Single Dose Vial from 2014 to 2026

    • 1.3.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of Pre-filled Syringe from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of For Children (2-10) from 2014 to 2026

    • 1.4.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of For Person (10-64) from 2014 to 2026

    • 1.4.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of For The old (≥65) from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of 23-Valent Pneumococcal Polysaccharide Vaccine Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of 23-Valent Pneumococcal Polysaccharide Vaccine by Major Types

      • 3.4.1 Market Size and Growth Rate of Single Dose Vial

      • 3.4.2 Market Size and Growth Rate of Pre-filled Syringe

    4 Segmentation of 23-Valent Pneumococcal Polysaccharide Vaccine Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of 23-Valent Pneumococcal Polysaccharide Vaccine by Major End-Users

      • 4.4.1 Market Size and Growth Rate of 23-Valent Pneumococcal Polysaccharide Vaccine for For Children (2-10)

      • 4.4.2 Market Size and Growth Rate of 23-Valent Pneumococcal Polysaccharide Vaccine for For Person (10-64)

      • 4.4.3 Market Size and Growth Rate of 23-Valent Pneumococcal Polysaccharide Vaccine for For The old (≥65)

    5 Market Analysis by Major Regions

    • 5.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Production Analysis by Top Regions

    • 5.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Analysis by Top Regions

    • 5.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.2 UK 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.3 France 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    6 Product Circulation of 23-Valent Pneumococcal Polysaccharide Vaccine Market among Top Countries

    • 6.1 Top 5 Export Countries in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 7.1 Germany 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 7.2 Germany 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    8. UK 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 8.1 UK 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 8.2 UK 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    9. France 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 9.1 France 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 9.2 France 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    10. Italy 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 10.1 Italy 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 10.2 Italy 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    11. Spain 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 11.1 Spain 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 11.2 Spain 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    12. Poland 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 12.1 Poland 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 12.2 Poland 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    13. Russia 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 13.1 Russia 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 13.2 Russia 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    14. Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 14.1 Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 14.2 Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    15. Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 15.1 Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 15.2 Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Top Countries

      • 16.3.1 Denmark 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

      • 16.3.2 Finland 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

      • 16.3.3 Norway 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

      • 16.3.4 Sweden 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

      • 16.3.6 Iceland 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Top Countries

      • 17.3.1 Belgium 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

      • 17.3.2 Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

      • 17.3.3 Luxembourg 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Landscape Analysis by Top Countries

      • 18.3.1 Estonia 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

      • 18.3.2 Latvia 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

      • 18.3.3 Lithuania 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Sanofi S.A.

      • 19.1.1 Sanofi S.A. Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Merck & Co.

      • 19.2.1 Merck & Co. Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 GlaxoSmithKline Plc.

      • 19.3.1 GlaxoSmithKline Plc. Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Pfizer Inc

      • 19.4.1 Pfizer Inc Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Serum Institute of India.

      • 19.5.1 Serum Institute of India. Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Eli Lilly and Company.

      • 19.6.1 Eli Lilly and Company. Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 AstraZeneca

      • 19.7.1 AstraZeneca Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Sanofi SA

      • 19.8.1 Sanofi SA Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Biogen Inc

      • 19.9.1 Biogen Inc Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Baxter International Inc

      • 19.10.1 Baxter International Inc Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    The List of Tables and Figures (Totals 75 Figures and 160 Tables)

    • Figure Product Picture

    • Figure Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of Single Dose Vial from 2014 to 2026

    • Figure Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of Pre-filled Syringe from 2014 to 2026

    • Figure Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of For Children (2-10) from 2014 to 2026

    • Figure Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of For Person (10-64) from 2014 to 2026

    • Figure Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate of For The old (≥65) from 2014 to 2026

    • Figure Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure UK 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure France 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Italy 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Spain 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Poland 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Russia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Canada 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Finland 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Norway 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania 23-Valent Pneumococcal Polysaccharide Vaccine Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of 23-Valent Pneumococcal Polysaccharide Vaccine Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of 23-Valent Pneumococcal Polysaccharide Vaccine

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of 23-Valent Pneumococcal Polysaccharide Vaccine by Different Types from 2014 to 2026

    • Table Consumption Share of 23-Valent Pneumococcal Polysaccharide Vaccine by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Single Dose Vial

    • Figure Market Size and Growth Rate of Pre-filled Syringe

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of 23-Valent Pneumococcal Polysaccharide Vaccine by Different End-Users from 2014 to 2026

    • Table Consumption Share of 23-Valent Pneumococcal Polysaccharide Vaccine by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of For Children (2-10)

    • Figure Market Size and Growth Rate of For Person (10-64)

    • Figure Market Size and Growth Rate of For The old (≥65)

    • Table Europe 23-Valent Pneumococcal Polysaccharide Vaccine Production by Major Regions

    • Table Europe 23-Valent Pneumococcal Polysaccharide Vaccine Production Share by Major Regions

    • Figure Europe 23-Valent Pneumococcal Polysaccharide Vaccine Production Share by Major Countries and Regions in 2014

    • Table Europe 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Major Regions

    • Table Europe 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Major Regions

    • Table Germany 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table UK 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table France 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Italy 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Spain 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Poland 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Russia 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in 23-Valent Pneumococcal Polysaccharide Vaccine Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Germany 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Germany 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Germany 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table UK 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table UK 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table UK 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table UK 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table France 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table France 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table France 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table France 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Italy 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Italy 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Italy 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Italy 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Spain 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Spain 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Spain 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Spain 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Poland 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Poland 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Poland 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Poland 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Russia 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Russia 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Russia 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Russia 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) 23-Valent Pneumococcal Polysaccharide Vaccine Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries 23-Valent Pneumococcal Polysaccharide Vaccine Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Sanofi S.A.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi S.A.

    • Figure Sales and Growth Rate Analysis of Sanofi S.A.

    • Figure Revenue and Market Share Analysis of Sanofi S.A.

    • Table Product and Service Introduction of Sanofi S.A.

    • Table Company Profile and Development Status of Merck & Co.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck & Co.

    • Figure Sales and Growth Rate Analysis of Merck & Co.

    • Figure Revenue and Market Share Analysis of Merck & Co.

    • Table Product and Service Introduction of Merck & Co.

    • Table Company Profile and Development Status of GlaxoSmithKline Plc.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline Plc.

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline Plc.

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline Plc.

    • Table Product and Service Introduction of GlaxoSmithKline Plc.

    • Table Company Profile and Development Status of Pfizer Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer Inc

    • Figure Sales and Growth Rate Analysis of Pfizer Inc

    • Figure Revenue and Market Share Analysis of Pfizer Inc

    • Table Product and Service Introduction of Pfizer Inc

    • Table Company Profile and Development Status of Serum Institute of India.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Serum Institute of India.

    • Figure Sales and Growth Rate Analysis of Serum Institute of India.

    • Figure Revenue and Market Share Analysis of Serum Institute of India.

    • Table Product and Service Introduction of Serum Institute of India.

    • Table Company Profile and Development Status of Eli Lilly and Company.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly and Company.

    • Figure Sales and Growth Rate Analysis of Eli Lilly and Company.

    • Figure Revenue and Market Share Analysis of Eli Lilly and Company.

    • Table Product and Service Introduction of Eli Lilly and Company.

    • Table Company Profile and Development Status of AstraZeneca

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca

    • Figure Sales and Growth Rate Analysis of AstraZeneca

    • Figure Revenue and Market Share Analysis of AstraZeneca

    • Table Product and Service Introduction of AstraZeneca

    • Table Company Profile and Development Status of Sanofi SA

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi SA

    • Figure Sales and Growth Rate Analysis of Sanofi SA

    • Figure Revenue and Market Share Analysis of Sanofi SA

    • Table Product and Service Introduction of Sanofi SA

    • Table Company Profile and Development Status of Biogen Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biogen Inc

    • Figure Sales and Growth Rate Analysis of Biogen Inc

    • Figure Revenue and Market Share Analysis of Biogen Inc

    • Table Product and Service Introduction of Biogen Inc

    • Table Company Profile and Development Status of Baxter International Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Baxter International Inc

    • Figure Sales and Growth Rate Analysis of Baxter International Inc

    • Figure Revenue and Market Share Analysis of Baxter International Inc

    • Table Product and Service Introduction of Baxter International Inc

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US